Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women.
Diabetologia
; 47(3): 571-574, 2004 Mar.
Article
in En
| MEDLINE
| ID: mdl-14762655
ABSTRACT
AIMS/HYPOTHESIS:
Our aim was to investigate the effect of long-term administration of raloxifene, a selective estrogen receptor modulator, on insulin sensitivity, glucose tolerance and plasma lipid concentrations in a group of postmenopausal women.METHODS:
A total of 24 women with postmenopausal osteoporosis were consecutively enrolled and randomly assigned to take raloxifene, 60 mg/day for 12 months or placebo. At baseline and after 6 and 12 months, in each subject insulin sensitivity (M-index) was assessed by means of an euglycaemic hyperinsulinaemic clamp. Plasma concentrations of total cholesterol, triglycerides and HDL-cholesterol were also measured and glucose tolerance was evaluated.RESULTS:
In the raloxifene-treated group, the M index decreased after 6 and 12 months with respect to the placebo group (-21%, p=0.042 and -23%, p=0.018, respectively). Neither fasting plasma glucose nor glucose tolerance changed in the raloxifene-treated group, compared to the placebo group. Low density lipoprotein cholesterol concentrations decreased at 12 months (-13%, p=0.047). CONCLUSION/INTERPRETATION:
A long-term treatment with raloxifene in osteoporotic, otherwise healthy post-menopausal women can reduce insulin sensitivity without affecting glucose tolerance.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Postmenopause
/
Raloxifene Hydrochloride
/
Selective Estrogen Receptor Modulators
/
Insulin
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Diabetologia
Year:
2004
Document type:
Article
Affiliation country:
Italy